The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer

Positron emission tomography (PET) incorporated with X-ray computed tomography (PET/CT) or magnetic resonance imaging (PET/MRI) is increasingly being used as a diagnostic tool for prostate cancer (PCa). In this review, we describe and evaluate the clinical performance of some Food and Drug Administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mei, Zelchan, Roman, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599369/
https://www.ncbi.nlm.nih.gov/pubmed/36289795
http://dx.doi.org/10.3390/biomedicines10102533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599369/
https://www.ncbi.nlm.nih.gov/pubmed/36289795
http://dx.doi.org/10.3390/biomedicines10102533

Ejemplares similares